All publications

Export 168 results:
Author [ Title(Desc)] Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
I
Geretti AM, White E, Beloukas A, Orkin C, Tostevin A, Tilston P, Chadwick D, Leen C, Sabin CA, Dunn DT et al..  2016.  Impact of Transmitted Thymidine Analogue Mutations on Responses to First-Line ART. Conference on Retroviruses and Opportunistic Infections (CROI) 2016.
Klein M, Odueyungbo A, Scherrer A, Ledergerber B, Fearnhill E, Sabin CA, Hogg R, Cozzi-Lepri A, Gill J, Tan D et al..  2011.  Impact of Viral Subtype on Immunologic and Clinical Disease Progression in Antiretroviral-naïve HIV-infected Adults. 18th Conference on Retroviruses and Opportunistic Infections, 27 Feb - 2 Mar 2011.
De Luca A., Flandre P., Dunn DT, Zazzi M, Wensing A., Santoro MM, Günthard HF, Wittkop L., Kordossis T., Garcia F. et al..  2016.  Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. J Antimicrob Chemother. 71:1352-60.
White E, Dunn DT, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2015.  Imputing viral subtype in time to virological failure analyses. International Workshop on HIV Observational Databases (IWHOD) 2015.
UK HIV Drug Resistance Database.  2014.  The increasing genetic diversity of HIV-1 in the UK, 2002-2010. AIDS. 28:773-80.
Assoumou L., Brun-Vezinet F., Cozzi-Lepri A, Kuritzkes D., Phillips AN, Zolopa A., Degruttola V., Miller V., Costagliola D..  2008.  Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. J Infect Dis. 198:470-80.
Cozzi-Lepri A.  2008.  Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response. HIV Med. 9:27-40.
Takebe Y., Naito Y., Raghwani J., Fearnhill E, Sano T., Kusagawa S., Mbisa JL, Zhang H, Matano T., Leigh Brown A et al..  2014.  Intercontinental dispersal of HIV-1 subtype B associated with transmission among men who have sex with men in Japan. J Virol. 88:9864-76.
K
Smit E, White E, Clark D, Churchill D, Zhang H, Collins S, Pillay D, Tostevin A, Dunn DT, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2015.  K65R detected more frequently in HIV-1 subtype C viruses at virological failure. International HIV Drug Resistance Workshop, 2015.
Smit E, White E, Clark D, Churchill D, Zhang H, Collins S, Pillay D, Tostevin A, Dunn DT, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2015.  K65R detected more frequently in HIV-1 subtype C viruses at virological failure. Conference on Retroviruses and Opportunistic Infections (CROI) 2015.
L
Phillips AN, Dunn DT, Sabin CA, Pozniak A, Matthias R, Geretti AM, Clark J, Churchill D, Williams I, Hill T et al..  2005.  Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS. 19:487-94.
Phillips AN, Dunn DT, Sabin CA, Pozniak A, Matthias R, Geretti AM, Clark J, Churchill D, Williams I, Hill T et al..  2004.  Long term risk of development of drug resistance after starting antiretroviral therapy in routine clinical practice. 7th International Congress on Drug Therapy in HIV Infection, 14-17 November 2004.
UK Collaborative Group on HIV Drug Resistance, UK Collaborative HIV Cohort Study(UK CHIC).  2010.  Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin Infect Dis. 50:1275-85.
Cozzi-Lepri A, Dunn DT, Pillay D, Sabin CA, Fearnhill E, Phillips AN, UK HIV Drug Resistance Database and UK Collaborative HIV Cohort Study.  2008.  Long-term probability of detecting HIV drug resistance in drug-naive patients starting currently recommended first-line combination ART. 15th Conference on Retroviruses and Opportunistic Infections, February 2008.
Dolling D, Dunn DT, Sutherland K.A, Pillay D, Mbisa JL, Parry C.M, Post FA, Sabin CA, Cane P A.  2013.  Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. J Antimicrob Chemother. 68:2339-43.
M
Foster GM, Ambrose JC, Hue S, Conibear T, Fearnhill E, Abecasis AB, Leigh Brown A, Geretti AM, UK HIV Drug Resistance Database.  2011.  Mapping the circulation of HIV-1 recombinants among MSM. 18th Conference on Retroviruses and Opportunistic Infections, 27 Feb - 2 Mar 2011.
Harrison LJ, Dunn DT, Green H, Copas A.  2009.  Modelling the association between patient characteristics and the change over time in a disease measure using observational cohort data. Stat Med. 28:3260-75.
Volz EM, Le Vu S, Ratmann O, Tostevin A, Dunn D, Orkin C, O'Shea S, Delpech V, Brown A, Gill N et al..  2018.  Molecular Epidemiology of HIV-1 Subtype B Reveals Heterogeneous Transmission Risk: Implications for Intervention and Control.. J Infect Dis. 217(10):1522-1529.
Hughes GJ, Fearnhill E, Dunn DT, Lycett S, Rambaut A, Leigh Brown A.  2009.  Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom. PLoS Pathog. 5:e1000590.
Antiretroviral Therapy Cohort Collaboration(ART-CC), Canadian Observational Cohort Collaboration(CANOC), UK Collaborative HIV Cohort Study(UK CHIC), Collaboration of Observational HIV Epidemiological Research in Europe(COHERE).  2016.  Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis. AIDS. 30(3)